Single-Dose Intranasal Nanoparticle Vaccine for Respiratory Diseases
Author Information
Author(s): Ulery Bret D., Kumar Devender, Ramer-Tait Amanda E., Metzger Dennis W., Wannemuehler Michael J., Narasimhan Balaji
Primary Institution: Iowa State University
Hypothesis
Can a single-dose intranasal nanoparticle-based vaccine induce long-lived protective immunity against respiratory diseases caused by Yersinia pestis?
Conclusion
The nanoparticle-based vaccine induced long-lasting protective immunity against pneumonic plague with high antibody titers.
Supporting Evidence
- The nanoparticle vaccine induced a high titer and high avidity IgG1 antibody response.
- 100% of mice vaccinated with the nanoparticle formulation survived a lethal challenge.
- Histopathological analysis showed no signs of infection in vaccinated mice.
Takeaway
Researchers created a new type of vaccine that can be given just once through the nose and helps protect against a serious disease called pneumonic plague for a long time.
Methodology
Mice were vaccinated intranasally with nanoparticle-encapsulated F1-V and challenged with Yersinia pestis to assess protection.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
C57BL/6 mice, female, 8 weeks old.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website